Cisco intends to acquire Isovalent, a leader in open source cloud native networking and security, to bolster its secure networking capabilities across public clouds. The Isovalent team will join the Cisco Security Business Group once
Tags :Vischer
Proteomedix, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech are forming together a company called Onconetix. The transaction is implemented by the acquisition of Proteomedix for an all stock consideration. Onconetix’s commercial
Embarking on a groundbreaking journey, fintech start-up Evorest is transforming the landscape of rental deposits. The company specializes in the digital management of rental deposits, offering tenants a unique opportunity to invest their funds digitally
Swiss-based Swimrun, the owner of ÖTILLÖ, The Swimrun World Championship, and ÖTILLÖ Swimrun World Series, has acquired a majority stake in Swimrun USA. All Ödyssey races will join the ÖTILLÖ Swimrun World Series in 2024, contributing
In a strategic move to expand its presence in the cloud and managed services sector, funds advised by Bregal Unternehmerkapital (Bregal) have successfully acquired Netrics Group, one of Switzerland’s leading providers in this space,
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
Waterland Private Equity, along with the minority stakeholders of Netrics Holding, has formalized a share purchase agreement for the divestment of all shares in Netrics Group to Bregal Unternehmerkapital, a global private equity firm. Netrics
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China)
Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group,
